The human multidrug transporter P-glycoprotein (Pgp, ABCB1) contributes to the poor bioavailability of many anticancer and antimicrobial agents as well as to drug resistance at the cellular level. For rational design of effective Pgp inhibitors, a clear understanding of its mechanism of action and functional regulation is essential. In this study, we demonstrate that inhibition of Pgp-mediated drug transport by cis-(Z) Cellular expression of human P-glycoprotein (Pgp), 1 the product of the MDR1 gene, confers resistance to a broad variety of structurally unrelated chemotherapeutic agents and restricts bioavailability of many therapeutic drugs in experimental models (1, 2). Pgp is a 1280-amino acid plasma membrane protein that has two homologous halves separated by a linker region of about 80 amino acids (3). Each half of the protein contains a hydrophobic region with six putative transmembrane (TM) helices, followed by a cytoplasmic consensus ATPbinding/hydrolysis site (3). The TM regions are presumed to form the drug-translocating pathway (4), whereas the ATP sites, through ATP hydrolysis, provide the necessary driving force for transport (5, 6).
1 the product of the MDR1 gene, confers resistance to a broad variety of structurally unrelated chemotherapeutic agents and restricts bioavailability of many therapeutic drugs in experimental models (1, 2) . Pgp is a 1280-amino acid plasma membrane protein that has two homologous halves separated by a linker region of about 80 amino acids (3) . Each half of the protein contains a hydrophobic region with six putative transmembrane (TM) helices, followed by a cytoplasmic consensus ATPbinding/hydrolysis site (3) . The TM regions are presumed to form the drug-translocating pathway (4) , whereas the ATP sites, through ATP hydrolysis, provide the necessary driving force for transport (5, 6) .
Pgp-mediated drug transport is inhibited by a number of structurally unrelated compounds known as reversing agents or modulators (for review see Ref. 2) . Although some of the modulators are currently being tested for their clinical effectiveness, there remains a growing need for molecules with higher efficacy (7) (8) (9) . To develop such compounds, a clear knowledge of the mechanisms of action of the existing repertoire is essential. Some of the Pgp modulators themselves, such as verapamil (10) and cyclosporin A (11) , are substrates of the pump and inhibit drug transport in a competitive manner without interrupting the catalytic turnover (catalytic cycle) of Pgp (12) (13) (14) (15) . However, for many others, the inhibitory mechanisms are yet to be fully understood.
Recent studies on the mechanism of action of Pgp modulators indicated an allosteric mode of action for several compounds. Martin et al. (16) demonstrated that inhibition of vinblastine transport by the anthranilic acid derivative XR9576 is not through direct physical competition for the drug translocating pathway, indicating an allosteric effect on substrate recognition or ATP hydrolysis (17) . A similar study suggested that the indolizin sulfone SR33557 affected vinblastine binding to Pgp through interaction with a site distinct from the site of substrate recognition (17) . Boer et al. (18) and Ferry et al. (19) have shown that modulators like dexniguldipine and prenylamine inhibited vinblastine interaction with Pgp by a non-competitive mechanism. Based on these and other similar studies, drug interaction sites of Pgp have been categorized into the following two discrete types: 1) transport sites, where translocation of drug across the lipid bilayer can occur, and 2) regulatory sites, which modulate Pgp function (20, 21) . Most of these studies investigated the effect of the modulators on substrate binding in isolated membranes, and relied exclusively on the kinetic parameters of substrate interaction with Pgp. However, little is known about the site(s) of modulator interaction with Pgp and the molecular mechanism by which the allosteric site(s) communicate with the other domains to inhibit drug transport.
Based on our prior studies (21, 22) and studies of other groups (23), we have proposed an allosteric mode of action for Pgp inhibitors with a thioxanthene backbone. In this study using a photoaffinity compound [
125 I]iodoarylazidoprazosin ([ 125 I]IAAP) as a transport substrate, we provide experimental evidence for an allosteric modulator site in Pgp through which drug transport is inhibited by preventing substrate transloca-tion and dissociation, without interfering with the initial step of substrate recognition. 3 H]cyclosporin A was purchased from Amersham Biosciences. Monoclonal antibody UIC2 was obtained from Immunotech (Westbrook, ME), and FITC-labeled anti-mouse IgG2a secondary antibody was purchased from Pharmingen. The human Pgp-specific polyclonal antibody PEPG13 was a generous gift from the laboratory of Dr. Michael M. Gottesman, NCI, National Institutes of Health. Goat anti-rabbit IgG conjugated with horseradish peroxidase was obtained from Invitrogen.
EXPERIMENTAL PROCEDURES

Chemicals-cis-(Z)-Flupentixol
Cell Lines and Plasmid Construction-Previously characterized mouse cell line NIH3T3 fibroblasts (drug-sensitive cell line) and the drug-resistant wild-type human Pgp-expressing NIHMDR1 cells (14) were used for this study. In addition, two cell lines NIHMDR1-WT and NIHMDR1-F983A were generated. NIHMDR1-WT and NIHMDR1-F983A were created by stepwise selection of NIH3T3 cells transfected with pHaMDR1 and pHaMDR1-F983A plasmids, respectively. The plasmid pHa-MDR1, which contains the human MDR1 cDNA in its entirety, was kindly provided by S. Kane (City of Hope, Duarte, CA) (24) . To construct the vector pHaMDR1-F983A, the NsiI-XhoI fragment of the previously described plasmid pTM1MDR1 containing the F983A mutation (25) was cloned into the corresponding sites of pHaMDR1. The region corresponding to the NdeI-PstI fragment within pHaMDR1-F983A including the insertion points and the flanking regions was sequenced in its entirety in both directions by automated sequencing (PRISM Ready Reaction DyeDeoxy Terminator Sequencing Kit, PerkinElmer Life Sciences). The plasmids pHaMDR1 and pHaMDR1-F983A were calcium phosphate-transfected into NIH3T3 cells and selected with vincristine. Clones were then picked and cultured to confluency. A stepwise selection was carried out with increasing concentrations of vincristine to generate NIHMDR1-WT and NIH-MDR1-F983A cell lines that were able to grow in the presence of 1 M vincristine. For maintenance of the cultures, cells were grown in monolayers at 37°C in the presence of 5% CO 2 , in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), as described earlier (15) . Pgp-expressing cells were maintained in the presence of respective drugs that were used for their selection.
[ 125 I]IAAP Accumulation in Intact Cells-0.5 ϫ 10 6 cells/well were grown in monolayers in a 24-well tissue culture plate at 37°C in the presence of 5% CO 2 in DMEM supplemented with 10% FBS (DMEM ϩ 10% FBS). Cells were washed once with 1 ml/well of DMEM ϩ 10% FBS 15 min prior to the initiation of the assay. The assay was initiated by incubating cells with 1.5 nM [ 125 I]IAAP in 0.3 ml of DMEM ϩ 10% FBS under subdued light (to avoid photocross-linking) at 37°C in the presence of 5% CO 2 . After incubation for varying times, cells were washed twice with 1 ml/well ice-cold PBS. Washed cells were harvested by treatment with 0.5 ml/well trypsin/EDTA at 37°C for 15 min. Harvested cells were diluted in 5 ml of Biosafe II scintillation fluid and mixed well by vortexing. Radioactivity associated with the cells was measured in a scintillation counter. Cells washed with ice-cold PBS immediately after addition of the assay mix was used as the "0"-min time point, and the value for accumulated 
SDS-PAGE and Immunoblot
Analysis-Electrophoresis and immunoblot analyses were performed as described previously (22) . Human Pgp-specific polyclonal antibody PEPG13 was used at a dilution of 1:4000 for detection of the wild-type and the mutant Pgps. A goat anti-rabbit IgG conjugated with horseradish peroxidase, at a dilution of 1:10000, was used as secondary antibody. Horseradish peroxidase-conjugated secondary antibody bound to the nitrocellulose was detected by using the horseradish peroxidase-catalyzed luminal-based chemiluminescence reaction (ECL Western blotting system) kit from Amersham Biosciences. The light emission signal was captured on a Kodak BioMax MR film.
Quantification of Radioactivity in Protein Bands-To determine the amount of [ 125 I]IAAP photocross-linked to Pgp, the radioactivity associated with each band was quantified from the dried gels by exposing to a PhosphorImager screen and analyzed using a STORM 860 PhosphorImaging system (Amersham Biosciences). Values were expressed either in arbitrary units or as percentage of a control experiment.
UIC2 Reactivity Shift Assay-Cells grown in monolayers were harvested by trypsinization, washed, and resuspended in IMDM supplemented with 5% FBS. 0.5 ϫ 10 6 cells were incubated at 37°C for 30 min with 5 g of the monoclonal antibody UIC2 in 0.4 ml of IMDM ϩ 5% FBS. Following incubation, cells were diluted with IMDM to 4.5 ml and centrifuged at 200 ϫ g for 7 min. Washed cell pellets were resuspended in 0.4 ml of IMDM ϩ 10% FBS containing 1 g of the FITC-conjugated anti-mouse IgG and incubated at 37°C for 30 min under subdued light. Cells were washed two times with IMDM ϩ 5% FBS and resuspended in 0.4 ml of cold PBS and analyzed in a fluorescence-assisted cell sorter (FACS). Wherever mentioned, cells were preincubated at 37°C for 3 min with 5 M cyclosporin A, 5 M cis-(Z)-flupentixol, or 1 mM sodium orthovanadate prior to addition of UIC2. The fluorescence intensity associated with cells was expressed on a log scale.
RESULTS
cis-(Z)-Flupentixol Induces an Elevated Level of Substrate ([ 125 ]IAAP) Association with Pgp-expressing Cells-cis-(Z)-
Flupentixol and certain structurally related analogs are potent inhibitors of Pgp-mediated drug transport (26 -28) . Characterization of its effect on substrate binding (23) suggested an allosteric mode of action for the modulator (21, 22) ; however, the exact mechanism of action remained unresolved. To understand the mechanism better, we developed a cell-based assay suitable for studying both Pgp-mediated transport and Pgp- (Fig. 2A) . Because vanadate trapping requires ATP hydrolysis, the lack of reversal in starved cells suggested that the cells were effectively depleted of ATP.
To (Fig. 3A) . Inclusion of 5 M cyclosporin A in the efflux medium had no effect on the rate of (Fig. 3C, autoradiogram) , during which almost 20% of the total [
125 I]IAAP molecules associated with NIHMDR1 cells was released to the extracellular medium. This suggested that most of the [ 125 I]IAAP released during the initial rapid phase was not associated with Pgp but instead remained free inside the cell. These molecules, not in complex with Pgp, most likely accumulated because of inhibition of outward transport. On the other hand, at 90 min, the amount of photocross-linked [ 125 I]IAAP was reduced to 58% compared the initial level (at 0 min) (Fig. 3C, autoradiogram) . This closely matched the percentage of [ 125 I]IAAP molecules released from the cells (58%) during the same period. Immunoblotting with Pgp-specific polyclonal antibody PEPG13 of the same samples showed equal amounts of Pgp present in each lane (Fig. 3C, immunoblot) . This result strongly suggested that (Fig. 4B, upper panel) . Similar results were obtained from experiments with membranes isolated from NIH-MDR1-WT and NIHMDR1-F983A cells (Fig. 4B, lower panel) .
A Single Amino Acid Substitution That Alters the Inhibitory Potential of cis-(Z)-Flupentixol Also Affects cis-(Z)-Flupentixolinduced Formation of Pgp-[
cis-(Z)-Flupentixol Induces a Conformational Change in Pgp That Is Distinct from the Change Induced by Substrates and
Competitive Inhibitors-Substrates and competitive inhibitors induce a conformational change in Pgp, which causes an increased reactivity to UIC2, a monoclonal antibody specific for a conformation-sensitive Pgp external epitope (32) . A similar increase in reactivity was observed with Pgp-expressing NIH-MDR1 cells in the presence of the competitive inhibitor cyclosporin A (32) (Fig. 5A) or the Pgp substrate vinblastine (data not shown), suggesting a conformational change in the proteinenhancing accessibility of the UIC2 epitope. Interestingly, cis-(Z)-flupentixol induced a clear decrease in the level of UIC2 binding to NIHMDR1 cells (Fig. 5A) indicating a conformational change distinct from that induced by the competitive inhibitor cyclosporin A. 1 mM sodium orthovanadate induced a more profound reduction in UIC2 binding (Fig. 5A) . Because vanadate inhibits Pgp-mediated drug transport by trapping Pgp in a transition-state conformation without physically competing for the substrate site, the result confirmed that reduced binding of UIC2 represented a mechanism of Pgp modulation that was distinct from competitive inhibition. To investigate the mechanistic significance of this conformational change, UIC2 reactivity was studied in cells expressing the Pgp mutant F983A, which has impaired sensitivity to inhibition by cis-(Z)-flupentixol (Fig. 5B) . cis-(Z)-Flupentixol was unable to induce any negative effect on UIC2 binding to NIHMDR1-F983A cells ( Fig. 5B) , suggesting that inhibition of transport and the conformational change induced by cis-(Z)-flupentixol could be mechanistically related. Because increased or decreased UIC2 reactivity induced by cyclosporin A or vanadate, respectively, was unaffected in NIHMDR1-F983A (Fig. 5B) , compared with that observed in NIHMDR1-WT cells, the possibility of a nonspecific effect could be ruled out.
cis-(Z)-Flupentixol Is Not a Transport Substrate for PgpCompetitive inhibitors such as cyclosporin A or verapamil are high affinity substrates of Pgp. When NIH3T3 and NIHMDR1 cells were incubated with cis-(Z)-[
3 H]flupentixol, no difference in intracellular accumulation of the radioactive compound was observed between the two cell types (Fig. 6A) , suggesting no Pgp-mediated outward transport of the modulator from the cells. Inclusion of the competitive inhibitor cyclosporin A did not have any effect (Fig. 6A) , further suggesting lack of cis-(Z)- (Fig. 6B) . This low level of [ 3 H]cyclosporin accumulation in NIHMDR1 cells was effectively increased to that of the control NIH3T3 cells by inclusion of 5 M rapamycin, a Pgp modulator, in the assay (Fig. 6B) . No comparable increase in [ 3 H]cyclosporin accumulation was observed in NIH3T3 cells (Fig. 6B) , demonstrating that cyclosporin A extrusion from NIHMDR1 cells was Pgp-dependent. DISCUSSION An allosteric mode of action has been proposed for a number of Pgp modulators (16 -20) . However, the exact mechanism by which these compounds inhibit Pgp-mediated drug transport is not yet fully understood. Knowledge about the mode of allosteric modulation will benefit rational design of Pgp inhibitors with higher efficacy. In the absence of high resolution structural information about Pgp, such studies rely heavily on biochemical and molecular biology approaches. In this study, we demonstrate that cis-(Z)-flupentixol, a thioxanthene derivative, allosterically inhibits Pgp-mediated drug transport by blocking translocation of substrate molecules and their subsequent dissociation from the transporter, without affecting the initial recognition of the substrate.
cis-(Z)-Flupentixol and its structurally related analogs are potent inhibitors of Pgp-mediated drug transport (26 -28) . A number of these thioxanthene derivatives do not physically compete for the substrate-binding site of Pgp (21, 23) , but instead they seem to interact at a distinct (allosteric) site within the protein (22) , indicating an allosteric mode of action. However, the molecular events leading to inactivation of the pump remained unresolved. To determine experimentally the mechanism of action of these modulators, we developed a cellbased assay that allows independent but simultaneous monitoring of substrate binding and substrate translocation by Pgp, without the need for changing experimental conditions. Because Pgp recruits substrate molecules directly from the lipid bilayer (33, 34) , the integrity and polarity of the plasma membrane were kept unperturbed using intact cells instead of inside-out membrane vesicles. The drug-sensitive NIH3T3 cells and the drug-resistant NIHMDR1 cells (NIH3T3 cells transfected with human MDR1 cDNA) provided a good signal to noise ratio in both drug extrusion and drug binding assays. The use of the photoaffinity analog of prazosin ([ 125 I]IAAP) as a substrate in the assay provided two distinct advantages. The high specific activity of the 125 I group in [ 125 I]IAAP allowed convenient detection of the molecule, whereas the photoactivable-N 3 group provided an efficient means to covalently immobilize the drug analog to its site of interaction, whenever required. Therefore, assessing both substrate recognition and substrate transport by Pgp could be monitored using the same experimental set up.
Although the photoaffinity analog [ 125 I]IAAP has been extensively used for studying substrate-binding properties of Pgp (35, 36) , no prior report has demonstrated Pgp-mediated transport of the molecule. In this study, we demonstrate that [ 125 I]IAAP is transported by Pgp out of the cells affecting a 2-fold reduction in its intracellular steady-state level (Fig. 1A) . Photocross-linking of [
125 I]IAAP with Pgp demonstrated a transient association between the two during transport (Fig.  1B) . Cyclosporin A, which competes for the Pgp substratebinding site (21) , and vanadate, which traps Pgp in a conformation with reduced affinity for substrates (21, 30) , independently blocked both recognition as well as transport of 125 I]IAAP by Pgp (Fig. 1) . On the other hand, metabolic starvation that depletes cells of intracellular ATP inhibited transport ( Fig. 2A) but not [
125 I]IAAP recognition (Fig. 2B) by Pgp. Because ATP (hydrolysis) is specifically required for the translocation step but not for substrate recognition, the results are in clear agreement with the proposed mechanism of action of Pgp. Therefore, the assay proves to be a reliable tool for studying the mode of action of Pgp modulators with unknown mechanisms of action. (Fig. 1B) . Although the association between Pgp and [ 125 I]IAAP was stabilized by cis-(Z)-flupentixol, the phenomenon was reversible, because removal of the cells to a drug-free medium resulted in dissociation of the complex (Fig. 3, B and C) ATP-dependent transport by Pgp involves three major steps as follows: 1) substrate recognition, 2) substrate translocation (coupled to ATP hydrolysis), and 3) substrate dissociation. It is conceivable that interference with any of these three steps may lead to inhibition of transport. Depletion of cellular ATP specifically inhibited the translocation step without affecting substrate recognition by Pgp (Fig. 2) , substantiating that ATP hydrolysis is required for substrate translocation and not for substrate binding. Interestingly, ATP depletion had no effect on stabilization of the Pgp-[
125 I]IAAP complex by cis-(Z)-flupentixol (Fig. 2) (Fig. 3B) . Consistent with that, a rapid initial phase, which had a rate constant comparable with that of the single phase [
125 I]IAAP release from NIH3T3 cells (data not shown) or from the cyclosporin A-inhibited NIHMDR1 cells (Fig. 3A) (Fig. 3B) . A direct (Fig. 4B ), drug transport function by which is not inhibited by cis-(Z)-flupentixol (Fig. 4A) . This emphasizes the mechanistic significance of the stable complex formation in inhibition of transport by cis-(Z)-flupentixol. Because the mutation F983A did not affect [
125 I]IAAP transport or the ability of cyclosporin A to block the substrate site (Fig. 4B ) and inhibit transport (Fig. 4A) , any global effect of the mutation can be ruled out.
Recently, by using bivalent cross-linking agents and cysteine-scanning mutagenesis, Loo and Clarke (4, 37) have mapped the substrate-binding site of Pgp. The proposed model shows the relative disposition of the putative transmembrane helices of Pgp and their contribution in constituting the substrate-binding site. Interestingly, residue Phe-983, which is necessary for cis-(Z)-flupentixol interaction with Pgp, maps well outside the substrate interaction site (4, 37) . This is in clear agreement with our experimental data showing no physical competition for the substrate site by cis-(Z)-flupentixol (Fig. 1B) and no transport of cis-(Z)-flupentixol by Pgp (Fig.  6A) . However, the spatial distinctness of the putative interaction site for cis-(Z)-flupentixol indicated a requirement for communication between the allosteric modulator site and the substrate translocating pathway. Communication of this nature often requires conformational changes in the protein. By using the monoclonal antibody UIC2, which is specific to a conformation-sensitive extracellular epitope of Pgp, we demonstrate that cis-(Z)-flupentixol induces a remarkable change in Pgp conformation, which is distinct from the changes induced by Pgp substrates (data not shown) or competitive inhibitors (Fig.  5A ). No such conformational change was induced by cis-(Z)-flupentixol in the Pgp mutant F983A, whereas the ability of the competitive inhibitor cyclosporin A to induce its characteristic change in conformation remained unaltered (Fig. 5B) , underscoring the functional distinctness of the allosteric site.
Allosteric regulations of ion channels and carrier proteins often play important functional roles in regulating ion fluxes across cellular membranes, and these have important implications in cell signaling and neuronal transmission (38) . Although allosteric modulation of ligand-gated channels is well documented, allosteric modulation of ABC transporters is a novel and emerging concept. The basic structural plan of ABC transporters includes two hydrophobic transmembrane domains and two cytosolic nucleotide-binding moieties per functional unit (39) . According to the most widely accepted model, the transmembrane regions associate with each other to form a single drug translocating pathway across the lipid bilayer, whereas the two nucleotide-binding sites constitute the catalytic domains that hydrolyze ATP to provide the driving force for the translocation step (1). The coupling of ATP hydrolysis to vectorial translocation of the drug substrate requires precise communication between the two domains. Stimulation of ATP hydrolysis by substrate binding to Pgp (6) and occlusion of the drug-binding site upon ATP hydrolysis (21, 30) suggested direct communication between the two domains via conformational changes (40 -42) . In this study, we demonstrate the presence of an allosteric modulator site within the Pgp capable of communicating with the substrate-binding/translocating site evidently through conformational change(s). Studying the details of the conformational change will reveal important information on the molecular events responsible for this communication. On the other hand, mapping the amino acid residues constituting the modulator site and the structural moieties of the modulator in contact with the site are likely to provide valuable clues for designing more efficient Pgp modulators. These avenues are currently being explored in our laboratory.
